Roche's Acquisition of Genentech

Posted: 2 Feb 2012

See all articles by Carliss Y. Baldwin

Carliss Y. Baldwin

Harvard Business School

Bo Becker

Stockholm School of Economics; Centre for Economic Policy Research (CEPR); ECGI

Vincent Dessain

Harvard Business School - Finance Unit; European Research Center

Date Written: September 28, 2011

Abstract

Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and cons of merging the two companies with different cultures, the value of Genentech, and the tactics of a hostile tender offer.

Suggested Citation

Baldwin, Carliss Y. and Becker, Bo and Dessain, Vincent, Roche's Acquisition of Genentech (September 28, 2011). Harvard Business School Finance Case No. 210-040, Available at SSRN: https://ssrn.com/abstract=1997201

Carliss Y. Baldwin (Contact Author)

Harvard Business School ( email )

Boston, MA 02163
United States

Bo Becker

Stockholm School of Economics ( email )

Drottninggatan 98
Dept. of Finance
111 60 Stockholm, 11160
Sweden

Centre for Economic Policy Research (CEPR) ( email )

London
United Kingdom

ECGI ( email )

c/o the Royal Academies of Belgium
Rue Ducale 1 Hertogsstraat
1000 Brussels
Belgium

Vincent Dessain

Harvard Business School - Finance Unit; European Research Center ( email )

Boston, MA 02163
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Abstract Views
1,991
PlumX Metrics